FDA Approves Besremi for Treatment of Adults With Essential Thrombocythemia by Madaline Spencer| Published on: Sep 3, 2026

FDA Approves Besremi for Treatment of Adults With Essential Thrombocythemia by Madaline Spencer| Published on: Sep 3, 2026 The US Food and Drug Administration (FDA) has approved Besremi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET). ET is a condition characterized by an overproduction of platelets. Abnormal blood clotting is common in these patients and may cause strokes or temporary stroke-like episodes, leg pain, swelling, pulmonary embolism, chest pain and difficulty breathing. A parodoxical problem in ET is abnormal bleeding, such as excessive nosebleeds, bleeding gums, or bleeding in the gastrointestinal tract. Other signs and symptoms include splenomegaly, weakness, headaches, or a sensation in the skin of burning, tingling, or prickling. Some people with ET have episodes of severe pain, redness, and swelling, which commonly occur in the hands and feet. https://checkrare.com/fda-approves-besremi-for-treatment-of-adults-with-essential-thrombocythemia/